Get startedLog in
    Picture of Avadel Pharmaceuticals logo

    AVDL — Avadel Pharmaceuticals News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousMid CapHigh Flyer
    All News

    Brief: Avadel Pharmaceuticals Announces FDA Approval Of Lumryz™ For The Treatment Of Cataplexy

    Picture of Avadel Pharmaceuticals logoAvadel Pharmaceuticals
    17/10/2024 18:36
    Oct 17 (Reuters) - Avadel Pharmaceuticals PLC  AVDL.O :
    * AVADEL PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF LUMRYZ™
(SODIUM
OXYBATE) EXTENDED-RELEASE ORAL SUSPENSION (CIII) FOR THE
TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS IN
PATIENTS 7 YEARS OF AGE AND OLDER WITH NARCOLEPSY
    * AVADEL PHARMACEUTICALS PLC - LUMRYZ GRANTED ORPHAN DRUG
EXCLUSIVITY THROUGH OCTOBER 16, 2031

Further company coverage:  AVDL.O 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Avadel Pharmaceuticals

    See all news